AR130076A1 - Restos escindibles por proteasas, y métodos de uso de los mismos - Google Patents
Restos escindibles por proteasas, y métodos de uso de los mismosInfo
- Publication number
- AR130076A1 AR130076A1 ARP230102010A ARP230102010A AR130076A1 AR 130076 A1 AR130076 A1 AR 130076A1 AR P230102010 A ARP230102010 A AR P230102010A AR P230102010 A ARP230102010 A AR P230102010A AR 130076 A1 AR130076 A1 AR 130076A1
- Authority
- AR
- Argentina
- Prior art keywords
- isolated
- polypeptide
- protease
- cleavable moiety
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/2408—Membrane-type matrix metalloproteinase-1 (3.4.24.80)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan polipéptidos aislados que incluyen un resto escindible que es un substrato para al menos una proteasa (por ej., MMP). Se divulgan moléculas activables que incluyen los polipéptidos aislados. Se divulgan métodos para preparar y usar los polipéptidos aislados y las moléculas activables que incluyen los polipéptidos aislados en una variedad de aplicaciones terapéuticas, de diagnóstico y profilácticas. Reivindicación 1: Un polipéptido aislado que comprende un resto escindible (CM) caracterizado porque comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 1 - 64, en donde el resto escindible es un substrato para una proteasa. Reivindicación 15: Un polipéptido aislado que comprende un resto escindible (CM) caracterizado porque comprende una secuencia de aminoácidos con una o más mutaciones de uno o dos aminoácidos de cualquiera de las SEQ ID Nº 1 - 64, en donde el CM es un substrato para una proteasa. Reivindicación 45: Un complejo polipeptídico caracterizado porque comprende uno o más de los polipéptidos aislados de una cualquiera de las reivindicaciones 1 - 44 unidos a un segundo polipéptido aislado. Reivindicación 46: Un polipéptido conjugado caracterizado porque comprende el polipéptido aislado de una cualquiera de las reivindicaciones 1 - 44 conjugado con un agente. Reivindicación 52: Una composición caracterizada porque comprende el polipéptido aislado de una cualquiera de las reivindicaciones 1 - 44, el complejo polipeptídico de la reivindicación 45, o el polipéptido conjugado de una cualquiera de las reivindicaciones 46 - 51, y un portador. Reivindicación 56: Una molécula de ácido nucleico aislada caracterizada porque codifica el polipéptido aislado de una cualquiera de las reivindicaciones 1 - 44. Reivindicación 57: Un vector caracterizado porque comprende la molécula de ácido nucleico aislado de la reivindicación 56. Reivindicación 58: Una célula caracterizada porque comprende la molécula de ácido nucleico aislado de la reivindicación 56 o el vector de la reivindicación 57.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370024P | 2022-08-01 | 2022-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130076A1 true AR130076A1 (es) | 2024-10-30 |
Family
ID=87760265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102010A AR130076A1 (es) | 2022-08-01 | 2023-07-31 | Restos escindibles por proteasas, y métodos de uso de los mismos |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4565260A1 (es) |
| JP (1) | JP2025525880A (es) |
| AR (1) | AR130076A1 (es) |
| TW (1) | TW202424184A (es) |
| WO (1) | WO2024030847A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN118146306A (zh) | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス，インコーポレイティド | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| IL255416B2 (en) | 2015-05-04 | 2024-06-01 | Cytomx Therapeutics Inc | Anti-CD71 antibodies, activatable anti-CD71 antibodies, preparations containing them and their uses |
| MX388350B (es) | 2015-05-04 | 2025-03-19 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| KR20190134654A (ko) | 2017-03-09 | 2019-12-04 | 싸이톰스 테라퓨틱스, 인크. | Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EA202090247A1 (ru) | 2017-07-14 | 2020-05-12 | Цитомкс Терапьютикс, Инк. | Антитела против cd166 и их применения |
| US12498367B2 (en) | 2017-07-20 | 2025-12-16 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| WO2019046652A1 (en) | 2017-08-30 | 2019-03-07 | Cytomx Therapeutics, Inc. | ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| US20200405890A1 (en) | 2018-02-21 | 2020-12-31 | Cytomx Therapeutics, Inc. | Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof |
| WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| EP3788077A1 (en) | 2018-05-02 | 2021-03-10 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| BR112021008526A2 (pt) | 2018-11-02 | 2021-08-10 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| JP2022523200A (ja) | 2019-02-26 | 2022-04-21 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
| WO2020236679A1 (en) | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| JP2022536511A (ja) | 2019-06-13 | 2022-08-17 | シートムエックス セラピューティクス，インコーポレイテッド | 癌の処置のための併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 |
| CN114173818A (zh) | 2019-06-13 | 2022-03-11 | 西托姆克斯治疗公司 | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途 |
| WO2021061867A1 (en) | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| MX2022008381A (es) | 2020-01-06 | 2022-08-08 | Cytomx Therapeutics Inc | Compuestos relacionados con auristatina, compuestos conjugados de auristatina y metodos de uso de ellos. |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
-
2023
- 2023-07-31 AR ARP230102010A patent/AR130076A1/es unknown
- 2023-07-31 TW TW112128642A patent/TW202424184A/zh unknown
- 2023-07-31 JP JP2025505852A patent/JP2025525880A/ja active Pending
- 2023-07-31 EP EP23758176.4A patent/EP4565260A1/en active Pending
- 2023-07-31 WO PCT/US2023/071306 patent/WO2024030847A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4565260A1 (en) | 2025-06-11 |
| JP2025525880A (ja) | 2025-08-07 |
| WO2024030847A1 (en) | 2024-02-08 |
| TW202424184A (zh) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130076A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130080A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130079A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130078A1 (es) | Substratos escindibles por proteasas, y métodos de uso de los mismos | |
| AR123978A1 (es) | Variantes de la interleucina-18 y métodos de uso | |
| Longworth | Conformations and interactions of excited states. II. Polystyrene, polypeptides, and proteins | |
| Offer et al. | N α-2-Mercaptobenzylamine-assisted chemical ligation | |
| Brik et al. | Protein synthesis by solid-phase chemical ligation using a safety catch linker | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| ATE118015T1 (de) | Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren. | |
| AR062867A2 (es) | Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| DK0531404T3 (da) | Ubiquitin-specifik protease | |
| DK161097C (da) | Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia | |
| AR040293A1 (es) | Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulo endoplasmico en plantas | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| He et al. | Chemical synthesis of histone H2A with methylation at Gln104 | |
| AR130640A1 (es) | Polipéptidos activados con proteasa | |
| DeLange et al. | Calf thymus histone III: Sequences of the amino-and carboxyl-terminal regions and of the regions containing lysyl residues modified by acetylation and methylation | |
| Segal et al. | The stereochemistry of substrate binding to chymotrypsin Aγ | |
| TR199900940T2 (xx) | Helikobakter pilori ile ilgili n�kleik ve amino asit sekanslar�. | |
| EP4085139A1 (en) | An activated cysteine-directed polypeptide ligation technique | |
| Beligere et al. | Synthesis of a three zinc finger protein, Zif268, by native chemical ligation | |
| Sobocińska et al. | Alanine scan of sialorphin and its hybrids with opiorphin: synthesis, molecular modelling and effect on enkephalins degradation | |
| Zhang et al. | A model for N-to-C direction in prebiotic peptide synthesis | |
| Li | Stereoselective peptide modification through 8-aminoquinoline controlled β‑C (sp3)‑H arylation at the C-terminal dipeptide |